StockNews.com initiated coverage on shares of OncoCyte (NASDAQ:OCX – Free Report) in a research report released on Thursday morning. The firm issued a sell rating on the stock.
Several other research firms also recently issued reports on OCX. Needham & Company LLC restated a buy rating and set a $4.25 price objective on shares of OncoCyte in a report on Thursday, May 16th. Stephens restated an equal weight rating and set a $4.00 price objective on shares of OncoCyte in a report on Wednesday, April 17th. Finally, Benchmark restated a speculative buy rating and set a $5.00 price objective on shares of OncoCyte in a report on Monday, April 15th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of Hold and a consensus target price of $4.06.
View Our Latest Analysis on OncoCyte
OncoCyte Stock Performance
OncoCyte (NASDAQ:OCX – Get Free Report) last issued its quarterly earnings data on Wednesday, May 15th. The company reported ($1.13) earnings per share for the quarter. OncoCyte had a negative net margin of 2,905.14% and a negative return on equity of 135.45%. The company had revenue of $0.18 million for the quarter. On average, sell-side analysts expect that OncoCyte will post -2.58 EPS for the current fiscal year.
OncoCyte Company Profile
OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.
Read More
- Five stocks we like better than OncoCyte
- The 3 Best Retail Stocks to Shop for in August
- Top 3 Defense Stocks That Should Be on Your Radar
- What Are Dividends? Buy the Best Dividend Stocks
- Why This Banking Stock Might Be Nearing the Bottom of Its Cycle
- Quiet Period Expirations Explained
- MarketBeat Week in Review – 7/8 – 7/12
Receive News & Ratings for OncoCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte and related companies with MarketBeat.com's FREE daily email newsletter.